Walgreens will pay the state of Alaska more than $100,000, as the pharmacy giant shells out more than $260 million to settle its alleged fraudulent over-dispensing of insulin pens as well as issues with its pricing schemes.

The state Department of Law’s Medicaid Fraud Control Unit announced the settlements Thursday afternoon, saying Walgreens will pay a total of $269.2 million nationwide. Alaska’s net proceeds in the settlements come out to about $59,000 in the insulin-pen matter and $56,000 in the pricing schemes.

According to the insulin-pen settlement, from 2006 through 2017 Walgreens “exceeded the prescription amount and falsified information on claims submitted for reimbursement to Medicare and Medicaid” in pen prescriptions’ quantities and durations.

“Pursuant to the settlement, Walgreens admitted to multiple factual statements including programming its computer system to define a full box of five insulin pens as the minimum dispensing package size,” state prosecutors wrote. “This definition prevented Walgreens pharmacists from being able to dispense fewer than five pens even though a patient’s prescription called for less pens than a box of five.”

The pricing-schemes case was linked to Walgreens’ Prescription Savings Club, in which the costs of some drugs billed to Medicaid were higher than the usual costs charged otherwise.

“In doing so, Walgreens’ obtained more money in reimbursements from the states’ Medicaid program for sales of such drugs than it was entitled to receive,” state prosecutors wrote.

Both negotiations with Walgreens were conducted by the National Association of Medicaid Fraud Control Units.

Copyright 2019 KTVA. All rights reserved.